[Ip-health] EU overlooks public health in IP Enforcement Directive

Press HAI Europe Press at haieurope.org
Fri Apr 1 00:37:23 PDT 2011

EU overlooks public health in IP Enforcement Directive 

1 April 2011


Health Action International (HAI) Europe has identified numerous
shortcomings in the European Commission's Report and Analysis on the
Directive on Intellectual Property (IP) Enforcement, and calls on the
Commission to consider the broader social impact of the Directive's
measure, namely access to medicines.


In its response to the European Commission's consultation on the Report
on the IP Enforcement Directive, submitted yesterday, HAI Europe
underlines the Commission's failure to consider the public health
dimension of IP enforcement. Glaring omissions reveal how the analysis
process failed to solicit the views of a broad range of stakeholders,
namely civil society, while granting business stakeholders multiple
opportunities to contribute.


The application of the IP Enforcement Directive could have a chilling
effect on the legitimate parallel trade of medicines, which would reduce
competition and drive up the costs of medicines, impacting on national
healthcare systems and citizens. Such consequences were not explored in
the Commission's analysis and are absent from the report. 


"IP enforcement can impact on the availability of generic medicines and
the affordability of medicines throughout Europe. Failing to consider
these implications is not in line with the EU's commitment to ensure
health in all policies," said Katrina Perehudoff, HAI Europe Project


"Access to medicines in countries with large poor populations could also
be under threat if the EU attempts to export its stringent IP
enforcement system through bilateral trade agreements, as it has done in
the past" said Terri Beswick, HAI Europe Project Officer.




The full HAI Europe Response is available at:


For more information please contact Katrina Perehudoff:
katrina at haieurope.org 




More information about the Ip-health mailing list